Covid-19 treatments: latest on research

Effective treatments for Covid-19 could help change the course of this pandemic – from saving lives to reducing the pressure on healthcare systems. A collective global effort is needed to fund, research, develop and bring effective treatments to people, as soon as possible.

When will we have effective treatments? 

Research into treatments for Covid-19 is moving at an incredible speed – with thousands of studies in progress and more than 200 potential therapies being explored. 

Large randomised clinical trials, such as the World Health Organization’s Solidarity clinical trial(opens in a new tab) and the UK’s RECOVERY trial(opens in a new tab), are essential for learning which treatments are safe and effective.

Most of the current research focuses on repurposed drugs – if shown to be effective, these could be rapidly rolled out across the world. It will take much longer to develop new safe and effective drugs that are specific to Covid-19.


We need a range of treatments for Covid-19 to cover all stages of the disease.

How we’re supporting research 

We launched the COVID-19 Therapeutics Accelerator together with the Bill & Melinda Gates Foundation and Mastercard.

This is a large-scale collaboration to research, develop and bring effective treatments to market quickly and accessibly. The studies funded so far(opens in a new tab) include evaluating approved drugs and creating platforms for exploring new potential treatments.

Find out how to apply for funding from or donate to the Therapeutics Accelerator(opens in a new tab).

Treatments for everyone 

Any – and all – effective treatments for Covid-19 must be available to everyone around the world. Those who need them most, not those who can afford to buy them, should have access first.

The ACT Accelerator(opens in a new tab), a global collaboration of governments and international organisations, was set up to support the development, production and equitable access to all tools that will help protect people against Covid-19.


More opinion

Read more articles on Covid-19.

Related content